Asia Pathogenomics (APG), a Taiwanese biotech company, is pioneering advancements in infectious disease diagnostics through its innovative metagenomic Next-Generation Sequencing (mNGS) technology.
Recently, APG signed a Memorandum of Understanding with Illumina Taiwan to enhance mNGS applications, aiming to improve the accuracy and speed of pathogen detection.
🧬 mNGS is a technique used in genomics to analyze genetic material obtained directly from environmental samples. This method allows for the comprehensive identification and characterization of microbial communities without the need for culturing organisms, making it valuable
Their APGSEQ® service can identify over 19,000 pathogens, achieving a 62% higher detection rate compared to traditional methods. This innovation positions APG as a key player in Taiwan's growing biomedicine sector, contributing to the country’s goal of becoming a leading hub for biomedical research in the Asia-Pacific region.
The partnership between Asia Pathogenomics (APG) and Illumina enhances the treatment of infectious diseases by advancing Metagenomic Next-Generation Sequencing (mNGS) technology.
This collaboration aims to improve the accuracy and speed of pathogen detection, enabling early treatment for patients with acute and severe infections. By integrating resources, APG and Illumina can address challenges such as drug-resistant pathogens that traditional methods often miss. Their combined efforts will facilitate precise diagnostics, ultimately leading to better patient outcomes and a stronger response to emerging infectious diseases in Taiwan and potentially beyond
Wanna learn more? dig in 🥗
[1] Asia Pathogenomics, Illumina signs MoU to further mNGS for infectious diseases | Healthcare+ B2B https://www.taiwan-healthcare.org/en/news-detail?id=0ryouh1nwtdlzfqb
[2] Transforming Pathology Labs: The Role of Laboratory Information Systems in Hospitals https://www.hhmglobal.com/knowledge-bank/news/in-singapore-precise-joins-illumina-for-public-health-study
[3] PRECISE ILLUMINA Partnership Agreement https://www.npm.sg/news-and-events/press-releases/precise-illumina-partnership-agreement/
[4] Illumina to Donate US $60 Million in Sequencing Capabilities to Establish a Global Pathogen Genomics Initiative https://investor.illumina.com/news/press-release-details/2021/Illumina-to-Donate-US-60-Million-in-Sequencing-Capabilities-to-Establish-a-Global-Pathogen-Genomics-Initiative/default.aspx
[5] Illumina, Trivitron collaborate for development, expansion of NGS-based tests in India - ET HealthWorld https://health.economictimes.indiatimes.com/news/diagnostics/illumina-trivitron-collaborate-for-development-expansion-of-ngs-based-tests-in-india/90201479
Comments